Article
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Gastroenterology - 1 Oct 2016
Gane Edward, Poordad Fred, Wang Stanley, Asatryan Armen, Kwo Paul Y, Lalezari Jacob, Wyles David L, Hassanein Tarek, Aguilar Humberto, Maliakkal Benedict, Liu Ran, Lin Chih-Wei, Ng Teresa I, Kort Jens, Mensa Federico J
Abstract excerpt
BACKGROUND & AIMS: The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment week 12 (SVR12) in noncirrhotic patients infected with hepatitis C virus (HCV) genotypes (GTs) 1-6. We describe 2 open-label phase 2 studies investigating the efficacy and safety of ABT-493 plus ABT-530 with or without ribavirin (RBV) in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.